CA
KDNY

CHI Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

CHI Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-135,000
Closed -$3.13M – 29
2023
Q1 		$3.13M Buy
+135,000
New +$3.22M 0.83% 15

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CHI Advisors's KDNY Position: Q2 2023 in Review

CHI Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 135,000 shares — an estimated $3.13M sold.

CHI Advisors first reported a position in KDNY in Q1 2023 and held it in 1 quarter. The position peaked at $3.13M in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • CHI Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • CHI Advisors sold 135,000 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.13M.
  • CHI Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • CHI Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $3.13M in Q1 2023.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.